Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors

Samsung Bioepis and Phrontline will co-develop two investigational antibody-drug conjugate (ADC) assets directed against targets expressed in a broad range of cancers

Collaboration will add a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis’ oncology portfolio
Phrontline will be responsible for creating bispecific, dual-payload ADCs using its bispecific antibody and dual-linker payload (DLP) platforms
Samsung Bioepis receives an exclusive license from Phrontline for one TOP1i payload for development, manufacturing, and commercialization of ADC therapeutics

• 페북
• 트윗
• 카톡
• 기타